Neurology Central

BrainStorm scraps initial access to NurOwn® for amyotrophic lateral sclerosis

BrainStorm Cell Therapeutics Inc. (NY, USA; Petach Tikva, Israel), a leading developer of adult stem cell technologies for neurodegenerative diseases, have announced that after careful consideration of the newly enacted ‘Right to Try’ (RTT) Act, it will not make NurOwn® available under this legislation at this time.
To view restricted content, please:

Leave A Comment